Table I.
Efficacy of narrow-band ultraviolet B (NB-UVB) and cyclosporine (CsA) treatment for atopic dermatitis
| Measure | NB-UVB group |
CsA group |
p-value | ||||
|---|---|---|---|---|---|---|---|
| Baseline Mean ± SD (range) |
Week 12 Mean ± SD (range) |
p-value | Baseline Mean ± SD (range) |
Week 12 Mean ± SD (range) |
p-value | ||
| WI-VAS (points) | 9.4 ± 0.9 (7–10) | 4.0 ± 1.1 (3–7) | < 0.0001 | 9.5± 0.8 (7–10) | 6.9 ± 1.0 (5–9) | < 00001 | < 0.0001 |
| EASI (points) | 41.7 ± 6.6 (31.4–49.7) | 30.0 ± 9.9 (15.3–46.5) | < 0.0001 | 44.5 ± 4.9 (35.4–49.4) | 36.8 ± 4.6 (26.7–43.3) | < 0.0001 | 0.03 |
| DLQI (points) | 10.7 ± 2.1 (6–14) | 4.9 ± 1.7 (2–7) | < 0.0001 | 12.2 ± 2.5 (8–16) | 8.5 ± 2.5 (4–15) | < 0.0001 | < 0.0001 |
| AIS (points) | 13.5 ± 2.4 (10–17) | 4.0 ± 1.1 (2–7) | < 0.0001 | 13.9 ± 1.8 (11–17) | 5.9 ± 0.9 (4–9) | < 0.0001 | < 0.0001 |
WI-VAS: Worst Itch Visual Analogue Scale; EASI: Eczema Area and Severity Index; DLQI: Dermatology Life Index Quality; AIS: Athens Insomnia Scale; SD: standard deviation.